SCHEMBL322186

SCHEMBL322186

O=C(O)NCCc1ccccc1I

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.49
CYP2C19 P33261 2/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
TAAR1 Q96RJ0 1/20 0.47
HIF1A Q16665 1/20 0.43
MTNR1A P48039 3/20 0.42
MTNR1B P49286 1/20 0.42
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
CA12 O43570 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
LTA4H P09960 2/20 0.40
PLA2G2A P14555 2/20 0.40
LMNA P02545 1/20 0.40
PKM P14618 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15486991 0.84 MTNR1A (0.61) CYP1A2CYP2C19MTNR1AMTNR1BMEN1
SCHEMBL29676881 0.80 MTNR1A (0.49) CYP1A2CYP2C19CYP2D6CYP2C9TAAR1
SCHEMBL18765551 0.80 MTNR1A (0.49) CYP1A2CYP2C19CYP2D6CYP2C9TAAR1
SCHEMBL5309632 0.79 MPO (0.56) CYP2D6TAAR1HIF1ACA12CA2
SCHEMBL10348018 0.79 ALDH1A1 (0.54) TAAR1MTNR1AMTNR1BMEN1KMT2A
SCHEMBL6921461 0.78 CYP1A2 (0.49) CYP1A2CYP2C19CYP2D6CYP2C9HIF1A
SCHEMBL4598193 0.78 MTNR1A (0.46) CYP1A2CYP2C19CYP2D6CYP2C9HIF1A
SCHEMBL6700589 0.78 MTNR1A (0.46) CYP1A2CYP2C19CYP2D6CYP2C9HIF1A
SCHEMBL1180411 0.78 HIF1A (0.67) TAAR1HIF1ANPC1RAB9ALMNA
SCHEMBL3638162 0.78 TAAR1 (0.56) TAAR1HIF1AMTNR1AMTNR1BKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210380548-A1 Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family CTXT PTY LIMITED (AU) 2021-12-09 US disclosed
EP-3676266-A1 FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY Ctxt Pty Ltd (AU) 2020-07-08 EP disclosed
WO-2019043139-A1 FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY CTXT PTY LIMITED (AU) 2019-03-07 WO disclosed
EP-2590951-B1 BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS PFIZER LTD (GB) 2015-01-07 EP disclosed
US-8772293-B2 Chemical compounds PFIZER LIMITED (GB) 2014-07-08 US disclosed
EP-2590951-A1 BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS Pfizer Limited (GB) 2013-05-15 EP disclosed
WO-2012004743-A1 BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS PFIZER LIMITED (GB) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210380548-A1 Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family KAT5, KAT6A, KAT2A CYP1A2 4070/4885CYP2C19 4830/4885CYP2D6 4049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.